LM Advisors LLC Buys Shares of 2,206,443 Liquidia Co. (NASDAQ:LQDA)

LM Advisors LLC bought a new position in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 2,206,443 shares of the company's stock, valued at approximately $25,948,000. Liquidia accounts for about 4.3% of LM Advisors LLC's investment portfolio, making the stock its 5th biggest position. LM Advisors LLC owned 2.61% of Liquidia at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of LQDA. BNP Paribas Financial Markets lifted its holdings in shares of Liquidia by 735.1% in the third quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company's stock valued at $1,402,000 after purchasing an additional 123,402 shares in the last quarter. Barclays PLC grew its stake in shares of Liquidia by 265.0% in the 3rd quarter. Barclays PLC now owns 99,984 shares of the company's stock worth $999,000 after acquiring an additional 72,591 shares in the last quarter. Whitefort Capital Management LP lifted its position in shares of Liquidia by 119.8% during the third quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company's stock valued at $17,020,000 after purchasing an additional 927,546 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Liquidia by 855.3% during the third quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company's stock worth $2,354,000 after purchasing an additional 210,753 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Liquidia by 144.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company's stock worth $3,903,000 after purchasing an additional 230,820 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on LQDA shares. Wells Fargo & Company assumed coverage on Liquidia in a report on Friday, December 20th. They issued an "overweight" rating and a $20.00 target price for the company. HC Wainwright reiterated a "buy" rating and set a $29.00 target price on shares of Liquidia in a research note on Thursday, March 20th. Scotiabank restated an "outperform" rating on shares of Liquidia in a research report on Thursday, March 20th. Finally, Needham & Company LLC lifted their price target on shares of Liquidia from $19.00 to $25.00 and gave the stock a "buy" rating in a report on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $26.63.

Liquidia Price Performance

Shares of NASDAQ:LQDA traded down $0.48 during trading on Monday, hitting $14.61. 297,569 shares of the company were exchanged, compared to its average volume of 933,806. The company has a market cap of $1.25 billion, a PE ratio of -8.99 and a beta of 0.07. Liquidia Co. has a 52-week low of $8.26 and a 52-week high of $16.81. The stock has a 50 day moving average of $15.10 and a 200 day moving average of $12.44.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The firm had revenue of $2.92 million for the quarter, compared to analysts' expectations of $4.60 million. Sell-side analysts forecast that Liquidia Co. will post -1.51 EPS for the current fiscal year.

Insider Activity

In other Liquidia news, insider Rajeev Saggar sold 2,445 shares of Liquidia stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total transaction of $31,785.00. Following the completion of the sale, the insider now directly owns 267,943 shares in the company, valued at $3,483,259. The trade was a 0.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Roger Jeffs sold 22,343 shares of the stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $263,200.54. Following the completion of the transaction, the chief executive officer now directly owns 1,019,177 shares in the company, valued at approximately $12,005,905.06. This represents a 2.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 71,245 shares of company stock worth $843,326 in the last three months. Corporate insiders own 30.10% of the company's stock.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).